Bradykinin and B 2 receptor antagonism in rat and human articular Chondrocytes

British Journal of Pharmacology

Volumn 162, Issue 3, 2011, Pages 611-622

  Meini, S ^a   Cucchi, P ^a   Catalani, C ^a   Bellucci, F ^a   Giuliani, S ^a   Maggi, C A ^a  

^a Menarini Ricerche SpA   (Italy)

Author keywords

B2 receptor antagonists; bradykinin; cartilage; chondrocytes; Hoe 140; Icatibant; interleukin 6; interleukin 8; MEN16132; osteoarthritis

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 6 ISOPROPOXY 9 OXO 2 XANTHENECARBOXYLIC ACID; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BRADYKININ; BRADYKININ B1 RECEPTOR ANTAGONIST; BRADYKININ B2 RECEPTOR ANTAGONIST; BRADYKININ RECEPTOR; BRADYKININ[8 LEUCINE 9 DEARGININE]; DEXAMETHASONE; ICATIBANT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; INOSITOL PHOSPHATE; INTERLEUKIN 6; INTERLEUKIN 8; MEN 16132; MITOGEN ACTIVATED PROTEIN KINASE P38; NORDIHYDROGUAIARETIC ACID; PHOSPHOLIPASE C; UNCLASSIFIED DRUG; (4 AMINO 5 (4 (4 (2,4 DICHLORO 3 (2,4 DIMETHYL 8 QUINOLYLOXYMETHYL)PHENYLSULFONAMIDO)TETRAHYDRO 2H 4 PYRANOYLCARBONYL)PIPERAZINO) 5 OXOPENTYL)(TRIMETHYL)AMMONIUM; (4-AMINO-5-(4-(4-(2,4-DICHLORO-3-(2,4-DIMETHYL-8-QUINOLYLOXYMETHYL)PHENYLSULFONA MIDO)TETRAHYDRO-2H-4-PYRANOYLCARBONYL)PIPERAZINO)-5-OXOPENTYL)(TRIMETHYL )AMMONIUM; BRADYKININ B2 RECEPTOR; DRUG DERIVATIVE; ORNITHINE; SULFONAMIDE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; CARTILAGE CELL; CARTILAGE DEGENERATION; CELL CULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LIGAND BINDING; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RECEPTOR BLOCKING; RECEPTOR DENSITY; ANIMAL; ARTICULAR CARTILAGE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; KNEE; METABOLISM; RADIOASSAY; SPRAGUE DAWLEY RAT;

ANIMALS; BRADYKININ; CARTILAGE, ARTICULAR; CELLS, CULTURED; CHONDROCYTES; HUMANS; INOSITOL PHOSPHATES; INTERLEUKIN-6; INTERLEUKIN-8; KNEE; ORNITHINE; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, BRADYKININ B2; SULFONAMIDES;

EID: 78651458938     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01062.x     Document Type: Article

References (52)

1. Alexander SPH, Mathie A, Peters JA, (2009). Guide to receptors and channels (GRAC). Br J Pharmacol 158: S1-S239.
2. Altman RD, (2009). Practical considerations for the pharmacologic management of osteoarthritis. Am J Manag Care 15: S236-S243.
3. Alvarez-Soria MA, Largo R, Sanchez-Pernaute O, Calvo E, Egido J, Herrero-Beaumont G, (2007). Prostaglandin E 2 receptors EP 1 and EP 4 are up-regulated in rabbit chondrocytes by IL-1beta, but not by TNFalpha. Rheumatol Int 27: 911-917.
4. Arunlakshana O, Schild HO, (1959). Some quantitative uses of drug antagonists. Br J Pharmacol Chemother 14: 48-58.
5. Baragi VM, Dudley DT, Schrier DJ, (1989). The phosphatidylinositol response of chondrocytes in culture. Agents Actions 27: 428-430.
6. Bellucci F, Meini S, Cucchi P, Catalani C, Giuliani S, Zappitelli S, et al. (2004). The N-terminal of icatibant and bradykinin interact with the same Asp residues in the human B 2 receptor. Eur J Pharmacol 491: 121-125.
7. Bellucci F, Cucchi P, Catalani C, Giuliani S, Meini S, Maggi CA, (2009). Novel effects mediated by bradykinin and pharmacological characterization of B 2 receptor antagonism in human synovial fibroblasts. Br J Pharmacol 158: 1996-2004.
8. Bendre MS, Montague DC, Peery T, Akel NS, Gaddy D, Suva LJ, (2003). Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone 33: 28-37.
9. Benton HP, Jackson TR, Hanley MR, (1989). Identification of a novel inflammatory stimulant of chondrocytes. Early events in cell activation by bradykinin receptors on pig articular chondrocytes. Biochem J 258: 861-867.
10. Bianchi M, Broggini M, Balzarini P, Franchi S, Sacerdote P, (2007). Effects of nimesulide on pain and on synovial fluid concentrations of substance P interleukin-6 and interleukin-8 in patients with knee osteoarthritis: comparison with celecoxib. Int J Clin Pract 61: 1270-1277.
11. Bond AP, Lemon M, Dieppe PA, Bhoola KD, (1997). Generation of kinins in synovial fluid from patients with arthropathy. Immunopharmacology 36: 209-216.
12. Bondeson J, Blom AB, Wainwright S, Hughes C, Caterson B, van den Berg WB, (2010). The role of synovial macrophages and macrophage-produced mediators in driving inflammatory and destructive responses in osteoarthritis. Arthritis Rheum 62: 647-657.
13. Brenn D, Richter F, Schaible HG, (2007). Sensitization of unmyelinated sensory fibers of the joint nerve to mechanical stimuli by interleukin-6 in the rat: an inflammatory mechanism of joint pain. Arthritis Rheum 56: 351-359.
14. Cheng Y, Prusoff WH, (1973). Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
15. Cialdai C, Giuliani S, Valenti C, Tramontana M, Maggi CA, (2009). Effect of intra-articular MEN16132, a kinin B 2 receptor antagonist, on nociceptive response in monosodium iodoacetate-induced experimental osteoarthritis in rats. J Pharmacol Exp Ther 331: 1025-1032.
16. Clarke DL, Giembycz MA, Patel HJ, Belvisi MG, (2004). E-ring 8-isoprostanes inhibit ACh release from parasympathetic nerves innervating guinea-pig trachea through agonism of prostanoid receptors of the EP 3-subtype. Br J Pharmacol 141: 600-609.
17. Clausen PA, Flechtenmacher J, Haeuselmann HJ, Kuettner KE, Aydelotte MB, Iyer AP, (1996). Evidence of an eicosanoid contribution to IL-1 induction of IL-6 in human articular chondrocytes. Am J Ther 3: 101-108.
18. Cucchi P, Meini S, Bressan A, Catalani C, Bellucci F, Santicioli P, et al. (2005). MEN16132, a novel potent and selective nonpeptide antagonist for the human bradykinin B 2 receptor. In vitro pharmacology and molecular characterization. Eur J Pharmacol 528: 7-16.
19. Gaddum JH, Hameed KA, Hathway DE, Stephens FF, (1955). Quantitative studies of antagonists for 5-hydroxytryptamine. Q J Exp Physiol Cogn Med Sci 40: 49-74.
20. Goldring MB, Berenbaum F, (2004). The regulation of chondrocyte function by proinflammatory mediators: prostaglandins and nitric oxide. Clin Orthop Relat Res 427 (Suppl.): S37-S46
21. Goldring MB, Otero M, Tsuchimochi K, Ijiri K, Li Y, (2008). Defining the roles of inflammatory and anabolic cytokines in cartilage metabolism. Ann Rheum Dis 67: iii75-iii82.
22. Goldring SR, Goldring MB, (2004). The role of cytokines in cartilage matrix degeneration in osteoarthritis. Clin Orthop Relat Res 427 (Suppl.): S27-S36.
23. Guerne PA, Carson DA, Lotz M, (1990). IL-6 production by human articular chondrocytes. Modulation of its synthesis by cytokines, growth factors, and hormones in vitro. J Immunol 144: 499-505.
24. Henrotin YE, De Groote DD, Labasse AH, Gaspar SE, Zheng SX, Geenen VG, et al. (1996). Effects of exogenous IL-1β, TNFα, IL-6, IL-8 and LIF on cytokine production by human articular chondrocytes. Osteoarthritis Cartilage 4: 163-173.
25. Henrotin YE, Labasse AH, Simonis PE, Zheng SX, Deby GP, Famaey JP, et al. (1999). Effects of nimesulide and sodium diclofenac on interleukin-6, interleukin-8, proteoglycans and prostaglandin E 2 production by human articular chondrocytes in vitro. Clin Exp Rheumatol 17: 151-160.
26. Hock FJ, Wirth K, Albus U, Linz W, Gerhards HJ, Wiemer G, et al. (1991). Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol 102: 769-773.
27. Jackson A, Gu W, (2009). Transport properties of cartilaginous tissues. Curr Rheumatol Rev 5: 40-50.
28. Jeffrey JE, Aspden RM, (2007). Cyclooxygenase inhibition lowers prostaglandin E 2 release from articular cartilage and reduces apoptosis but not proteoglycan degradation following an impact load in vitro. Arthritis Res Ther 9: R129.
29. Kahle P, Saal JG, Schaudt K, Zacher J, Fritz P, Pawelec G, (1992). Determination of cytokines in synovial fluids: correlation with diagnosis and histomorphological characteristics of synovial tissue. Ann Rheum Dis 51: 731-734.
30. Kaneko S, Satoh T, Chiba J, Ju C, Inoue K, Kagawa J, (2000). Interleukin-6 and interleukin-8 levels in serum and synovial fluid of patients with osteoarthritis. Cytokines Cell Mol Ther 6: 71-79.
31. Kenakin T, (2006). Orthosteric drug antagonism. In:, Kenakin T, (ed.). A Pharmacology Primer: Theory, Application, and Methods, 2nd edn. Elsevier, Academic Press: London, pp. 99-126.
32. Lee CH, Shieh DC, Tzeng CY, Chen CP, Wang SP, Chiu YC, et al. (2008). Bradykinin-induced IL-6 expression through bradykinin B2 receptor, phospholipase C, protein kinase Cdelta and NF-kappaB pathway in human synovial fibroblasts. Mol Immunol 45: 3693-3702.
33. Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL, (2005). International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 57: 27-77.
34. Legendre F, Bogdanowicz P, Boumediene K, Pujol JP, (2005). Role of interleukin 6 (IL-6)/IL-6R-induced signal tranducers and activators of transcription and mitogen-activated protein kinase/extracellular. J Rheumatol 32: 1307-1316.
35. Li X, Ellman M, Muddasani P, Wang JH, Cs-Szabo G, van Wijnen AJ, et al. (2009). PGE 2 and its cognate EP receptors control human adult articular cartilage homeostasis and are linked to the pathophysiology of osteoarthritis. Arthritis Rheum 60: 513-523.
36. Livshits G, Zhai G, Hart DJ, Kato BS, Wang H, Williams FM, et al. (2009). Interleukin-6 is a significant predictor of radiographic knee osteoarthritis: the Chingford study. Arthritis Rheum 60: 2037-2045.
37. Meini S, Maggi CA, (2008). Knee osteoarthritis: a role for bradykinin? Inflamm Res 57: 351-361.
38. Meini S, Cucchi P, Bellucci F, Catalani C, Faiella A, Rotondaro L, et al. (2004). Site-directed mutagenesis at the human B 2 receptor and molecular modelling to define the pharmacophore of non-peptide bradykinin receptor antagonists. Biochem Pharmacol 67: 601-609.
39. Meini S, Cucchi P, Bellucci F, Catalani C, Giuliani S, Santicioli P, et al. (2007). Comparative antagonist pharmacology at the native mouse bradykinin B 2 receptor: radioligand binding and smooth muscle contractility studies. Br J Pharmacol 150: 313-320.
40. Meini S, Cucchi P, Catalani C, Bellucci F, Giuliani S, Santicioli P, et al. (2009). Pharmacological characterization of the bradykinin B 2 receptor antagonist MEN16132 in rat in vitro bioassays. Eur J Pharmacol 615: 10-16.
41. Meini S, Cucchi P, Catalani C, Bellucci F, Santicioli P, Giuliani S, et al. (2010). Radioligand binding characterization of the bradykinin B 2 receptor in the rabbit and pig ileal smooth muscle. Eur J Pharmacol 635: 34-39.
42. Miyazawa K, Mori A, Okudaira H, (1998). Regulation of interleukin-1β-induced interleukin-6 gene expression in human fibroblast-like synoviocytes by glucocorticoids. J Biochem 124: 1130-1137. (Pubitemid 29017302)
43. Molloy ES, Morgan MP, Doherty GA, McDonnell B, O'Byrne J, Fitzgerald DJ, et al. (2008). Mechanism of basic calcium phosphate crystal-stimulated matrix metalloproteinase-13 expression by osteoarthritic synovial fibroblasts: inhibition by prostaglandin E 2. Ann Rheum Dis 67: 1773-1779.
44. Pan ZK, Zuraw BL, Lung CC, Prossnitz ER, Browning DD, Ye RD, (1996). Bradykinin stimulates NF-kappaB activation and interleukin 1beta gene expression in cultured human fibroblasts. J Clin Invest 98: 2042-2049.
45. Poẑgan U, Caglic D, Rozman B, Nagase H, Turk V, Turk B, (2010). Expression and activity profiling of selected cysteine cathepsins and matrix metalloproteinases in synovial fluids from patients with rheumatoid arthritis and osteoarthritis. Biol Chem doi: 10.1515/bc.2010.035.
46. Regoli D, Barabé J, (1980). Pharmacology of bradykinin and related kinins. Pharmacol Rev 32: 1-46.
47. Sanchez C, Mateus MM, Defresne MP, Crielaard JM, Reginster JY, Henrotin YE, (2002). Metabolism of human articular chondrocytes cultured in alginate beads. Longterm effects of interleukin 1β and nonsteroidal antiinflammatory drugs. J Rheumatol 29: 772-782.
48. Schnabel M, Marlovits S, Eckhoff G, Fichtel I, Gotzen L, Vécsei V, et al. (2002). Dedifferentiation-associated changes in morphology and gene expression in primary human articular chondrocytes in cell culture. Osteoarthritis Cartilage 10: 62-70.
49. Valenti C, Cialdai C, Giuliani S, Lecci A, Tramontana M, Meini S, et al. (2005). MEN16132, a novel potent and selective nonpeptide kinin B 2 receptor antagonist: in vivo activity on bradykinin-induced bronchoconstriction and nasal mucosa microvascular leakage in anesthetized guinea pigs. J Pharmacol Exp Ther 315: 616-623.
50. Valenti C, Cialdai C, Giuliani S, Tramontana M, Quartara L, Maggi CA, (2008). MEN16132, a kinin B 2 receptor antagonist, prevents the endogenous bradykinin effects in guinea-pig airways. Eur J Pharmacol 579: 350-356.
51. Wang P, Zhu F, Lee NH, Konstantopoulos K, (2010). Shear-induced interleukin-6 synthesis in chondrocytes: roles of E prostanoid (EP) 2 and EP 3 in cAMP/protein kinase A and PI3-K/Akt-dependent NF-κB activation. J Biol Chem 285: 24793-24804.
52. Xie P, Browning DD, Hay N, Mackman N, Ye RD, (2000). Activation of NF-kappa B by bradykinin through a Galpha(q)-and Gbeta gamma-dependent pathway that involves phosphoinositide 3-kinase and Akt. J Biol Chem 275: 24907-24914.